[go: up one dir, main page]

WO1997013505A3 - UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE - Google Patents

UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE Download PDF

Info

Publication number
WO1997013505A3
WO1997013505A3 PCT/FR1996/001568 FR9601568W WO9713505A3 WO 1997013505 A3 WO1997013505 A3 WO 1997013505A3 FR 9601568 W FR9601568 W FR 9601568W WO 9713505 A3 WO9713505 A3 WO 9713505A3
Authority
WO
WIPO (PCT)
Prior art keywords
rar
apoptosis
specific agonist
agonist ligand
composition
Prior art date
Application number
PCT/FR1996/001568
Other languages
English (en)
Other versions
WO1997013505A2 (fr
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird, Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert filed Critical Cird
Priority to PL96326077A priority Critical patent/PL185826B1/pl
Priority to AU72209/96A priority patent/AU705993B2/en
Priority to US09/051,407 priority patent/US6593359B1/en
Priority to NZ319646A priority patent/NZ319646A/xx
Priority to EP96933502A priority patent/EP0854710A2/fr
Priority to BR9610967A priority patent/BR9610967A/pt
Priority to JP09514767A priority patent/JP3135266B2/ja
Priority to KR1019980702620A priority patent/KR19990064139A/ko
Publication of WO1997013505A2 publication Critical patent/WO1997013505A2/fr
Publication of WO1997013505A3 publication Critical patent/WO1997013505A3/fr
Priority to NO981592A priority patent/NO981592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Utilisation d'au moins un ligand agoniste spécifique aux récepteurs de type RAR-η dans la préparation d'une composition pharmaceutique destinée à augmenter le taux d'apoptose dans au moins une population cellulaire pour laquelle l'apoptose peut être induite par activation des récepteurs de type RAR-η. Cette composition peut servir notamment à traiter une maladie ou un désordre lié à une insuffisance du taux d'apoptose dans au moins une population cellulaire pour laquelle l'apoptose peut être induite par activation des récepteurs de type RAR-η. Utilisation d'au moins un ligand agoniste spécifique aux récepteurs de type RAR-η dans une composition cosmétique en tant qu'inducteur d'apoptose. Cette composition peut permettre de prévenir et/ou de lutter contre le vieillissement photoinduit ou chronologique de la peau.
PCT/FR1996/001568 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE WO1997013505A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL96326077A PL185826B1 (pl) 1995-10-09 1996-10-08 Zastosowanie specyficznego ligandu agonistycznegoZastosowanie specyficznego ligandu agonistycznegoRAR-y do zwiększenia stopnia apoptozyRAR-y do zwiększenia stopnia apoptozy
AU72209/96A AU705993B2 (en) 1995-10-09 1996-10-08 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US09/051,407 US6593359B1 (en) 1995-10-09 1996-10-08 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
NZ319646A NZ319646A (en) 1995-10-09 1996-10-08 Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis
EP96933502A EP0854710A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-$g(g) POUR AUGMENTER LE TAUX D'APOPTOSE
BR9610967A BR9610967A (pt) 1995-10-09 1996-10-08 Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele
JP09514767A JP3135266B2 (ja) 1995-10-09 1996-10-08 アポプトシス速度向上のためのＲＡＲ−γ−特異的アゴニストリガンドの使用
KR1019980702620A KR19990064139A (ko) 1995-10-09 1996-10-08 세포 소멸 속도를 증가시키는 감마-알에이알-특이성 작용 물질리간드의 용도
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR95/12179 1995-10-09
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US09/051,407 A-371-Of-International US6593359B1 (en) 1995-10-09 1996-10-08 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
US09/431,920 Division US6686386B1 (en) 1995-10-09 1999-11-02 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
US09/624,771 Division US6506796B1 (en) 1995-10-09 2000-07-25 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis
US09/801,664 Continuation US20010018456A1 (en) 1995-10-09 2001-03-09 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
US10/183,518 Continuation-In-Part US20030092758A1 (en) 1995-10-09 2002-06-28 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis

Publications (2)

Publication Number Publication Date
WO1997013505A2 WO1997013505A2 (fr) 1997-04-17
WO1997013505A3 true WO1997013505A3 (fr) 1997-05-29

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Country Status (16)

Country Link
US (4) US6593359B1 (fr)
EP (1) EP0854710A2 (fr)
JP (1) JP3135266B2 (fr)
KR (1) KR19990064139A (fr)
CN (1) CN1121857C (fr)
AU (1) AU705993B2 (fr)
BR (1) BR9610967A (fr)
CA (1) CA2231561A1 (fr)
FR (1) FR2739557B1 (fr)
HU (1) HUP9900453A3 (fr)
NO (1) NO981592L (fr)
NZ (1) NZ319646A (fr)
PL (1) PL185826B1 (fr)
RU (1) RU2188037C2 (fr)
TR (1) TR199800645T1 (fr)
WO (1) WO1997013505A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
EP1030662B1 (fr) * 1997-11-12 2006-08-02 F. Hoffmann-La Roche Ag Traitement des maladies immunes induites par les lymphocytes t auxiliaires de type 2
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US20080227868A1 (en) * 2004-03-26 2008-09-18 Volker Schehlmann Composition Comprising an Hdac Inhibitor in Combination with a Retinoid
US7713266B2 (en) * 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) * 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
WO2009065061A1 (fr) 2007-11-14 2009-05-22 Myoscience, Inc. Gestion de la douleur à l'aide du remodelage cryogénique
JP5642087B2 (ja) 2008-12-22 2014-12-17 ミオサイエンス インコーポレーティッド 冷媒および電源を備えた一体型凍結手術システム
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
MX367850B (es) * 2011-06-24 2019-09-09 Gri Bio Inc Prevención y tratamiento de condiciones inflamatorias.
EP2802279B1 (fr) 2012-01-13 2017-08-16 Myoscience, Inc. Aiguille cryogénique avec régulation de la zone de congélation
CN104159534B (zh) 2012-01-13 2017-02-22 肌肉科技股份有限公司 用于美容和其他处理的皮下低温重塑的皮肤保护
WO2013106860A1 (fr) 2012-01-13 2013-07-18 Myoscience, Inc. Système de filtration de sonde cryogénique
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
WO2014146126A1 (fr) 2013-03-15 2014-09-18 Myoscience, Inc. Méthodes et dispositifs cryogéniques de dissection par extrémité émoussée
WO2014146127A1 (fr) 2013-03-15 2014-09-18 Myoscience, Inc. Procédés et systèmes pour le traitement de la spasticité
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
US10940127B2 (en) 2015-11-25 2021-03-09 Io Therapeutics, Inc. Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
EP4349396A3 (fr) 2016-05-13 2024-05-01 Pacira CryoTech, Inc. Systèmes de localisation et de traitement par thérapie contre le froid
MX2018015352A (es) * 2016-06-10 2019-03-28 Io Therapeutics Inc Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
CA3069676A1 (fr) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. Composes retinoides et rexinoides immunomodulateurs en combinaison avec des modulateurs immunitaires pour l'immunotherapie du cancer
SG11202001479RA (en) 2017-08-31 2020-03-30 Io Therapeutics Inc Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3709918B1 (fr) 2017-11-15 2025-06-18 Pacira CryoTech, Inc. Systèmes intégrés de thérapie à froid et de stimulation électrique pour localiser et traiter des nerfs
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003682A1 (fr) * 1995-07-17 1997-02-06 Centre International De Recherches Dermatologiques C.I.R.D. Galderma Procedes de traitement de cancers a l'aide de 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003682A1 (fr) * 1995-07-17 1997-02-06 Centre International De Recherches Dermatologiques C.I.R.D. Galderma Procedes de traitement de cancers a l'aide de 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. CORBEIL ET AL.: "antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.", J. CLIN. INVEST., vol. 93, no. 5, 1994, pages 1981 - 1986, XP000646558 *
M.F. BOEHM ET AL.: "design and synthesis of potent retinoid-X receptor selective ligands that induce apoptosis in leukemia cells.", J. MED. CHEM., vol. 38, no. 16, 1995, pages 3146 - 3155, XP000615461 *
Z-M. SHAO ET AL.: "P53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells.", ONCOGENE, vol. 11, no. 3, 1995, pages 493 - 504, XP000575582 *

Also Published As

Publication number Publication date
PL185826B1 (pl) 2003-08-29
CN1121857C (zh) 2003-09-24
NO981592L (no) 1998-06-09
AU7220996A (en) 1997-04-30
JP3135266B2 (ja) 2001-02-13
HUP9900453A2 (hu) 1999-05-28
US6506796B1 (en) 2003-01-14
US6686386B1 (en) 2004-02-03
WO1997013505A2 (fr) 1997-04-17
NZ319646A (en) 2000-08-25
CA2231561A1 (fr) 1997-04-17
AU705993B2 (en) 1999-06-03
RU2188037C2 (ru) 2002-08-27
HUP9900453A3 (en) 1999-11-29
TR199800645T1 (xx) 1998-06-22
FR2739557A1 (fr) 1997-04-11
KR19990064139A (ko) 1999-07-26
PL326077A1 (en) 1998-08-17
NO981592D0 (no) 1998-04-07
CN1203528A (zh) 1998-12-30
FR2739557B1 (fr) 1997-11-14
US6593359B1 (en) 2003-07-15
EP0854710A2 (fr) 1998-07-29
BR9610967A (pt) 1999-03-02
US20010018456A1 (en) 2001-08-30
JPH11501661A (ja) 1999-02-09

Similar Documents

Publication Publication Date Title
WO1997013505A3 (fr) UTILISATION D&#39;UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D&#39;APOPTOSE
DE69535095D1 (de) Vorrichtung zum austeilen von gebrauchsfertiger visköser lösung sowie deren verwendung zum austeilen
DE69410279D1 (de) Reduktion von hautirritationen und hautwiderstand während einer iontophoresebehandlung
PL325956A1 (en) Application of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene in prophylaxis and treatment of the effects of encephalitis and chronic encephalaemia as well as degenerative nervous system affections
AU5756194A (en) Cosmetic applicator useful for cleansing, moisturizing and protecting the skin from diaper rash
PL312481A1 (en) Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such
TW350914B (en) Analytical system and method
TR199801501T1 (xx) Yeni form�lasyon.
MY119711A (en) Method of inhibiting photoaging of skin
CA2199993A1 (fr) Procede d&#39;administration de materiaux dans la peau et compositions utilisees lors de ce procede
FI950465A7 (fi) Läpäisevä laastari lääkityksen antamiseksi ihoon
FR2715845B1 (fr) Composition cosmétique et/ou dermatologique contenant du vinaigre.
ATE164998T1 (de) Verwendung eines bradykinin-antagonisten in einer kosmetischen, pharmazeutischen oder dermatologischen zusammensetzung und die erhaltene zusammensetzung
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
AU694702B2 (en) W/O emulsion with a high electrolyte content, and its use in dermo-cosmetics, in particular for treating phenomena of irritation and/or of sensitive skin
WO1997003188A3 (fr) Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux
DE69712578D1 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
EP1190672A3 (fr) Dispositif et méthode d&#39;analyse statistique de l&#39;intervalle QT en fonction des modifications de l&#39;intervalle RR
AU687687B2 (en) Novel compositions based on a synergistic combination of one or more vrd ligands and retinoids
PT1070253E (pt) Utilização de receptores hroralfa para o rastreio de substâncias úteis para o tratamento de aterosclerose
ATE251906T1 (de) Verwendung von vitamine e acetat
AU7485996A (en) Neuropeptide y-y5 receptor
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
NO975473L (no) Opplösning for direkte påföring på huden for å kontrollere kveg- og saueparasitter
FR2719475B1 (fr) Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96198769.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN HU JP KR MK MX NO NZ PL RU TR US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN HU JP KR MK MX NO NZ PL RU TR US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996933502

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2231561

Country of ref document: CA

Ref document number: 2231561

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/00645

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1199800300

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/002761

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 514767

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980702620

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 319646

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09051407

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1996933502

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980702620

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980702620

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996933502

Country of ref document: EP